Tag: Q422

Source: Dr. Yi Chen  (9/17/22) The purpose behind this complementary study is to potentially expand the treatment’s target patient population, noted an H.C. Wainwright & Co. report. ASLAN Pharmaceuticals Ltd. (ASLN:NASDAQ), to complement its in-progress TREK-AD dose-ranging eblasakimab trial for moderate to severe atopic dermatitis (eczema), plans a second study, TREK-DX, in the subpopulation of patients […]